P012 - Content Variant Corporate Level 3

The WAO Henning Løwenstein Research Award 

To a scientist who has shown excellence within the field of allergy  

Over the last few decades allergy has increased in prevalence to become the most common chronic disease in modern societies. The causes for this sudden change are not entirely clear, although they seem to be linked to ‘modern lifestyle’.

For many years doctors have advised patients to avoid allergen exposure as a means of reducing symptoms; but recent research seem to indicate that there is no simple dose-response relationship between exposure and symptoms.

Pharmacotherapy is in widespread use all over the world to treat respiratory allergic disease. Although effective in controlling symptoms, pharmacotherapy does not change the course of disease and it does not prevent increases in prevalence.

It appears that allergy immunotherapy is the only treatment to treat the cause, induce immunological tolerance and to prompt disease modification. Disease modification implies long term effect, prevention of asthma in children with allergic rhinitis and prevention of new allergies.

In ALK we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people with allergies all over the world.

The WAO Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. The 2015 Award includes €20,000* and a travel grant to attend the Symposium of Specific Allergy, SOSA, in Rome, Italy, 19-21 November, 2015.

Application Guidelines